The end of July 2023 saw another reputed Global Pharma appoint Aagami for finding partner for ready to commercialize Denosumab Biosimilar in...
Published : 21 Jul 2023
Read MoreAagami are glad to announce that a Japan and US based Biotech has appointed Aagami to support fundraising and partnering of their portfolio of in...
Published : 10 Jul 2023
Read MoreAagami has a new client, new assignment for Market Landscape Research. Once completed, the client would appoint Aagami to support their partnerin...
Published : 11 Jun 2023
Read MoreAagami successfully completed BIO International Convention 2023 (June 5-8) in Boston with 45+ one-on-one meetings with decision makers in Biotech, Pha...
Published : 10 Jun 2023
Read MoreAagami has been appointed by a Pennsylvania Pharma to support their strategic partnering needs. Client is a Biopharma R&D focused company tha...
Published : 15 May 2023
Read MoreA Portland based Biotech has appointed Aagami to support their strategic investment and partnering needs. The CEO of client company has kno...
Published : 12 May 2023
Read MoreAn existing client from San Francisco has awarded a new assignment to Aagami for supporting their fund-raising needs again. The Client is a...
Published : 01 May 2023
Read MoreSuccess Story: Aagami secures funding for US client developing First-in-Class Non-Opioid Analgesic for Pain Relief We are pleased to announce tha...
Published : 22 Apr 2023
Read MoreAagami has been appointed as consultant by another Korean client which has developed world’s first digital monitoring and management solution for Th...
Published : 10 Apr 2023
Read MoreAagami has a new client. This time it is an Award-winning New York biotech specializing in molecular engineering, RNAi and CRISPR/Cas9 technologi...
Published : 07 Apr 2023
Read More